This section is intended for patients prescribed ADCETRIS. If you are a member of the public click here. If you are a UK healthcare professional click here.
ADCETRIS (brentuximab vedotin) is subject to additional monitoring. This will allow quick identification of new safety information.
You can help by reporting any side effects you may get. If you get any side effects whilst taking ADCETRIS, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed on this website or in the patient information leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects you can help provide more information on the safety of this medicine.
Takeda Oncology, 
and ADCETRIS are registered trademarks of Takeda Pharmaceutical Company Limited.
Other trademarks are the property of their respective owners.
© Takeda UK Limited, 2017
Registered office: Takeda UK Limited, Building 3, Glory Park, Glory Park Avenue, Wooburn Green, Bucks, HP10 0DF
Registered in England and Wales No. 3362860
UK/ADC/1707/0053h - August 2017
The link you have selected is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.
Please confirm you wish to follow this link.
You are now leaving the ADCETRIS.co.uk website. The link you have selected will now take you to the Takeda UK website.
Please confirm you wish to follow this link.
You are now leaving the ADCETRIS.co.uk website. The link you have selected will now take you to the Takeda global website. Takeda UK does not manage or maintain the content of the global website.
Please confirm you wish to follow this link.
You are now leaving the ADCETRIS.co.uk website. The link you have selected will now take you to the Takeda global website. Takeda UK does not manage or maintain the content of the global website.
Please confirm you wish to follow this link.
UK/ADC/1707/0053u(1) - August 2018